Here's Why Catalyst Pharmaceutical ( CPRX ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Santhera extends Highbridge convertible bond to 30th September 2025
Ad hoc announcement pursuant to Art. ...
Why Catalyst Pharmaceutical ( CPRX ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Santhera Secures Agreement with GEN for the Distribution of AGAMREE® ( Vamorolone ) in Türkiye
Pratteln, Switzerland, 13 August, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. ( GEN ) for the distribution and promotion of AGAMREE® ( vamorolone ) in Türkiye for the treatment of Duchenne ...
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.
Rigel Pharmaceuticals, Inc. ( RIGL ) Hits Fresh High: Is There Still Room to Run?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Lambert Eaton Myasthenic Syndrome ( LEMS ) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer ( SCLC )
CORAL GABLES, Fla., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( Nasdaq: CPRX ) , a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and ...
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
CPRX gears up to report Q2 results as Firdapse sales rise, Agamree grows, and Fycompa faces a post-patent dip.
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
CORAL GABLES, Fla., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( Nasdaq: CPRX ) today announced the appointment of Daniel Curran, MD, to its Board of Directors.
Are Investors Undervaluing Catalyst Pharmaceuticals ( CPRX ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is the Market Bullish or Bearish on Catalyst Pharmaceuticals? - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
Catalyst Pharmaceuticals's CPRX short percent of float has risen 9.1% since its last report. The company recently reported that it has 8.92 million shares sold short, which is 9.35% of all regular shares that are available for trading.
Here's Why Catalyst Pharmaceutical ( CPRX ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Rising Cash Flows Make These 4 Stocks Worth Choosing Now
CPRX, STKL, GAMB and ORN are gaining attention as rising cash flows signal strength, flexibility and growth potential.
Buy These 4 Stocks With Solid Net Profit Margin to Maximize Returns
Let's take a look at four stocks, CPRX, GAMB, ORN and BWAY, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.
Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ET ...
Here's Why Catalyst Pharmaceutical ( CPRX ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.
Should Value Investors Buy Catalyst Pharmaceuticals ( CPRX ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Peering Into Catalyst Pharmaceuticals's Recent Short Interest - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
Catalyst Pharmaceuticals's CPRX short percent of float has risen 5.8% since its last report. The company recently reported that it has 8.17 million shares sold short, which is 8.57% of all regular shares that are available for trading.
Why Catalyst Pharmaceutical ( CPRX ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Catalyst Pharmaceutical ( CPRX ) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are Investors Undervaluing Catalyst Pharmaceuticals ( CPRX ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Catalyst Pharmaceuticals Gaining or Losing Market Support? - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
Catalyst Pharmaceuticals's CPRX short percent of float has risen 5.19% since its last report. The company recently reported that it has 7.73 million shares sold short, which is 8.1% of all regular shares that are available for trading.
Top 3 Health Care Stocks You'll Regret Missing This Quarter - Catalyst Pharmaceuticals ( NASDAQ:CPRX ) , Moleculin Biotech ( NASDAQ:MBRX )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
4 Stocks With Solid Net Profit Margins to Boost Portfolio Returns
Here we present four stocks, GLDD, TILE, CPRX and STRL, with solid net profit margins that can contribute to making a strong portfolio.
Preethi Sundaram Implements A Sell Strategy: Offloads $103K In Catalyst Pharmaceuticals Stock - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
Revealing a significant insider sell on June 12, Preethi Sundaram, Chief Strategy Officer at Catalyst Pharmaceuticals CPRX, as per the latest SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Sundaram sold 3,924 shares of Catalyst ...
Director Of Catalyst Pharmaceuticals Sold $5.22M In Stock - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
Revealing a significant insider sell on June 10, Patrick J McEnany, Director at Catalyst Pharmaceuticals CPRX, as per the latest SEC filing. What Happened: McEnany opted to sell 200,000 shares of Catalyst Pharmaceuticals, according to a Form 4 filing with the U.S. Securities and Exchange ...
If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Is Cencora, Inc. ( COR ) Stock Outpacing Its Medical Peers This Year?
Here is how Cencora (COR) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
CORAL GABLES, Fla., June 02, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) CPRX today announced the appointment of William ( Will ) T. Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews will report directly to the Company's President and Chief ...
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career ...
Santhera's Shareholders Approve all Board Proposals at Today's Annual General Meeting
Pratteln, Switzerland, May 20, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) today announces that its shareholders approved all motions by the Board of Directors at the Annual General Meeting ( AGM ) held today in Pratteln, Switzerland, with a large majority.
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference ...
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
CORAL GABLES, Fla., April 30, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( Nasdaq: CPRX ) , a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and ...
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025 - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
CORAL GABLES, Fla., April 30, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) CPRX, a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat ...
Santhera Publishes Agenda for its Annual General Meeting
Pratteln, Switzerland, April 29, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) today published the invitation to its Annual General Meeting ( AGM ) , which will be held on May 20, 2025, at 10:00 CEST at Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Switzerland.
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May ...
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET ...
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
CORAL GABLES, Fla., April 22, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) CPRX, a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat ...
Epilepsy Foundation of America Launches Comprehensive Epilepsy & Seizure Safe Classrooms Toolkit for K-12 Educators
BOWIE, Md., April 16, 2025 ( GLOBE NEWSWIRE ) -- The Epilepsy Foundation of America is proud to announce the release of the Epilepsy & Seizure Safe Classrooms Toolkit, a comprehensive educational resource designed to assist K-12 educators in creating safe and supportive classroom environments ...
Santhera shares updates on commercial rollout of AGAMREE®
Pratteln, Switzerland, April 16, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy ( DMD ) .
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst trading days in years, and almost no sector of the economy was spared.
Santhera proposes Dr. Melanie Rolli as new member of Board of Directors
Ad hoc announcement pursuant to Art. 53 LR ...
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day
Pratteln, Switzerland, March 24, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) announces that at its Capital Markets Day ( CMD ) in Zurich today, the Company will discuss the commercial progress with the global roll-out of AGAMREE® for the treatment of Duchenne Muscular Dystropy ( DMD ) .
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
CORAL GABLES, Fla., March 04, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) CPRX, a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat ...
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
CORAL GABLES, Fla., March 04, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( Nasdaq: CPRX ) , a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and ...
Full Year Trading Update
Ad hoc announcement pursuant to Art. 53 LR ...
